Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

Cover Podcast "Die Hypothese", featuring Elvira Mass

News categories: Outreach

“We have our macropahges under control!”

Our giant phagocytes in the liver are the “butlers” of the tissues: they not only fight bacteria, but also eat metabolic waste and even microplastics. “They also make sure that the neighboring cells are happy,” says developmental biologist and immunologist Prof. Dr. Elvira Mass from the LIMES Institute. In the new episode of Bonn University's podcast "die Hypothese" (the hypothesis), she discusses the thesis “We have our macropahges under control!” with host Denis Nasser.
View entry
News Icon

News categories: Publication

Multiple Sclerosis: Potential biomarker linked to progression and brain inflammation identified

Better ways to detect ongoing brain damage in multiple sclerosis (MS) are urgently needed. An international team of scientists, including ImmunoSensation³ member Prof. Anne-Katrin Pröbstel, has identified a molecular circuit that drives brain injury in MS. In a mouse model, blocking the enzyme Bruton's tyrosine kinase prevented harmful clustering of immune cell and brain tissue demage. Patient data revealed the same immune signaling pattern, suggesting strong translational potential for diagnosis. The study was recently published in Nature Immunology.
Full publication
Symbol Image

News categories: Publication

Instructions for building antibodies decoded

MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein in the myelin layer that surrounds the neurons in the brain. It is believed that these antibodies contribute to the destruction of this protective layer in the brain. Researchers at the University Hospital Bonn (UKB) and the Universities of Basel and Bonn, in collaboration with an international team, have now deciphered the construction plan of the anti-MOG antibodies.
View entry

Back to the news overview